Aliases & Classifications for Agnosia

MalaCards integrated aliases for Agnosia:

Name: Agnosia 12 20 53 44 15 17 70 32
Dyspraxia 12 53 6
Primary Visual Agnosia 20 70
Monomodal Visual Amnesia 20
Dyspraxia Syndrome 12
Visual Amnesia 20
Apraxias 70
Alexia 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4090
MeSH 44 D000377
NCIt 50 C84542
SNOMED-CT 67 42341009
ICD10 32 R48.1
UMLS 70 C0001816 C0002018 C0003635 more

Summaries for Agnosia

GARD : 20 Agnosia is characterized by an inability to recognize and identify objects and/or persons. Symptoms may vary, according to the area of the brain that is affected. It can be limited to one sensory modality such as vision or hearing; for example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, traumatic brain injury, dementia, a tumor, developmental disorders, overexposure to environmental toxins (e.g., carbon monoxide poisoning), or other neurological conditions. Visual agnosia may also occur in association with other underlying disorders. People with agnosia may retain their cognitive abilities in other areas. Treatment of primary agnosia is symptomatic and supportive; when it is caused by an underlying disorder, treatment of the disorder may reduce symptoms and help prevent further brain damage.

MalaCards based summary : Agnosia, also known as dyspraxia, is related to pain agnosia and amnestic disorder, and has symptoms including seizures, fever and dyspnea. An important gene associated with Agnosia is SIL1 (SIL1 Nucleotide Exchange Factor), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Cisatracurium and Flurbiprofen have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and temporal lobe, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A communication disorder that is a loss of ability to recognize objects, persons, sounds, shapes, or smells while the specific sense is not defective nor is there any significant memory loss.

NINDS : 53 Agnosia is a rare disorder characterized by an inability to recognize and identify objects or persons. People with agnosia may have difficulty recognizing the geometric features of an object or face or may be able to perceive the geometric features but not know what the object is used for or whether a face is familiar or not. Agnosia can be limited to one sensory modality such as vision or hearing. For example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, dementia, developmental disorders, or other neurological conditions. It typically results from damage to specific brain areas in the occipital or parietal lobes of the brain. People with agnosia may retain their cognitive abilities in other areas.

Wikipedia : 73 Agnosia is the inability to process sensory information. Often there is a loss of ability to recognize... more...

Related Diseases for Agnosia

Diseases in the Agnosia family:

Form Agnosia

Diseases related to Agnosia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
# Related Disease Score Top Affiliating Genes
1 pain agnosia 31.5 TRPV1 TRPA1 TCF21 TAC1 SCN9A POMC
2 amnestic disorder 30.9 PDYN OXT OPRM1 FOS
3 speech and communication disorders 30.4 TAC1 POMC OXT OPRM1 LIPN
4 schizophrenia 30.4 POMC PNOC PDYN OXT OPRM1 FOS
5 complex regional pain syndrome 30.2 TAC1 SCN9A POMC CALCA
6 anxiety 29.9 TAC1 POMC PNOC PDYN OXT OPRM1
7 rolandic epilepsy, mental retardation, and speech dyspraxia, x-linked 11.6
8 visual agnosia 11.6
9 apperceptive agnosia 11.5
10 auditory agnosia 11.5
11 childhood apraxia of speech 11.4
12 social emotional agnosia 11.4
13 tactile agnosia 11.4
14 finger agnosia 11.4
15 verbal auditory agnosia 11.4
16 integrative agnosia 11.4
17 astereognosia 11.4
18 form agnosia 11.3
19 topographical agnosia 11.3
20 developmental dyspraxia 11.3
21 associative agnosia 11.3
22 color agnosia 11.3
23 time agnosia 11.2
24 mirror agnosia 11.2
25 semantic agnosia 11.2
26 visual verbal agnosia 11.2
27 autotopagnosia 11.1
28 phonagnosia 11.1
29 prosopagnosia 11.1
30 developmental coordination disorder 11.1
31 cortical deafness 11.1
32 gerstmann syndrome 11.1
33 apraxia 11.0
34 alexia 11.0
35 kluver-bucy syndrome 11.0
36 foxp2-related speech and language disorders 11.0
37 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 11.0
38 agraphia 10.9
39 galactosemia i 10.9
40 rolandic epilepsy-speech dyspraxia syndrome 10.9
41 amusia 10.9
42 nominal aphasia 10.9
43 anosognosia 10.9
44 simultanagnosia 10.9
45 semantic dementia 10.9
46 craniofacial dyssynostosis with short stature 10.9
47 wieacker-wolff syndrome 10.9
48 mental retardation with language impairment and with or without autistic features 10.9
49 neurodevelopmental disorder with cerebellar atrophy and with or without seizures 10.9
50 alexithymia 10.9

Graphical network of the top 20 diseases related to Agnosia:



Diseases related to Agnosia

Symptoms & Phenotypes for Agnosia

UMLS symptoms related to Agnosia:


seizures; fever; dyspnea; vertigo; cachexia; abnormality of extrapyramidal motor function; headache; torticollis; clumsiness; syncope; scanning speech; cyanosis; edema; visual agnosia; icterus; signs and symptoms; signs and symptoms, digestive; other symbolic dysfunction; hot flushes; symptoms; muscle rigidity

MGI Mouse Phenotypes related to Agnosia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 CCK FAAH FOS NPFF OPRK1 OPRL1
2 homeostasis/metabolism MP:0005376 10.13 CCK FAAH FOS LIPN NPFF OPRK1
3 integument MP:0010771 10 FAAH FOS OPRK1 OPRL1 OPRM1 OXT
4 nervous system MP:0003631 9.8 CCK FAAH FOS OPRK1 OPRL1 OPRM1
5 normal MP:0002873 9.23 FAAH FOS OPRL1 OPRM1 SCN9A TAC1

Drugs & Therapeutics for Agnosia

Drugs for Agnosia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisatracurium Approved Phase 4 96946-41-7 62887
2
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
3
Dezocine Approved, Investigational Phase 4 53648-55-8 40841 3033053
4
Nalbuphine Approved Phase 4 20594-83-6 5360630 5311304
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
9
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
10
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
12
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Codeine Approved, Illicit Phase 4 76-57-3 5284371
15
Norepinephrine Approved Phase 4 51-41-2 439260
16
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
17
Butorphanol Approved, Illicit, Vet_approved Phase 4 42408-82-2, 58786-99-5 5361092
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
19
Tolvaptan Approved Phase 4 150683-30-0 216237
20
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
23
Morphine Approved, Investigational Phase 4 57-27-2 5288826
24
Remifentanil Approved Phase 4 132875-61-7 60815
25
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
26
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
27
Nefopam Approved, Investigational Phase 4 13669-70-0
28
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
29
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
30
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
31
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
32
Trichostatin A Experimental Phase 4 58880-19-6
33 Neuromuscular Blocking Agents Phase 4
34 Neurotransmitter Agents Phase 4
35 Excitatory Amino Acid Antagonists Phase 4
36
protease inhibitors Phase 4
37 Dexamethasone 21-phosphate Phase 4
38 BB 1101 Phase 4
39 HIV Protease Inhibitors Phase 4
40 Sympatholytics Phase 4
41 Anesthetics, Dissociative Phase 4
42 Sodium Channel Blockers Phase 4
43 Anti-Arrhythmia Agents Phase 4
44 Diuretics, Potassium Sparing Phase 4
45 Opiate Alkaloids Phase 4
46 Cola Phase 4
47 Gastrointestinal Agents Phase 4
48 Antiemetics Phase 4
49 Antineoplastic Agents, Hormonal Phase 4
50 Hormone Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 206)
# Name Status NCT ID Phase Drugs
1 Analgesia After Total Knee Arthroplasty: Randomized Controlled Trial Comparing (a) Periarticular Multimodal Technique With (B) Continuous Femoral Nerve Block + Posterior Capsular Injection Unknown status NCT00869037 Phase 4 Periarticular Injection;CFNB + Posterior Capsular Injection
2 Postoperative Patient Controlled Epidural Analgesia After Total Knee Arthroplasty With 2ug/ml Fentanyl Combine With 0.2% Ropivacaine or 0.2% Levobupivcaine Unknown status NCT01158586 Phase 4 Levobupivacaine
3 Intravenous Versus Caudal Supplementation of Ketamine for Postoperative Pain Control in Children,A Double-blind Controlled Clinical Trial. Unknown status NCT00532662 Phase 4 S(+)-ketamine
4 The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery Unknown status NCT02503826 Phase 4 Sufentanil;Sufentanil;Sufentanil;Midazolam;propofol;cisatracurium
5 Effect of Dexmedetomidine Combined With Dezocine and Flubiprofen for Postoperative Intravenous Patient Controlled Analgesia After Colorectal Surgery Unknown status NCT03014713 Phase 4 Dezocine;Flubiprofen;Dexmedetomidine
6 Ketamine and Postoperative Analgesia in Children Unknown status NCT00200564 Phase 4 ketamine
7 Intraoperative and Postoperative Analgesia for Laparoscopic Surgery. Completed NCT00772187 Phase 4 morphine;intrathecal analgesia (morphine);general anesthesia (fentanyl)
8 Intravenous Continuous Infusion of Dexamethasone Plus Tramadol Combined With Standard Morphine Patient-Controlled Analgesia After Total Abdominal Hysterectomy Completed NCT00564603 Phase 4 Dexamethasone Sodium Phosphate Injection
9 Postoperative Pain and Systemic Inflammatory Stress Response (SIRS) After Preoperative Analgesia With Clonidine or Levobupivacaine Completed NCT00860899 Phase 4 clonidine, levobupivacaine
10 The Combination Effect of Dexmedetomidine and Morphine in Postoperative Patient-Controlled Analgesia Completed NCT00800826 Phase 4 dexmedetomidine
11 Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction Completed NCT01593566 Phase 4 0.25% Bupivacaine;0.5% Bupivacaine
12 Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks Completed NCT02523235 Phase 4 ropivacaine 0.2%
13 Does Postoperative Administration of Oral Oxycodone With/Without Naloxone, Reduce the Duration of Epidural Analgesia in Patients Undergoing Cystectomy Without Impairing Its Benefits? A Randomized, Double Blind Controlled Trial Completed NCT02516059 Phase 4 oxycodone/naloxone;Oxycodone;Placebo
14 Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section Completed NCT03450499 Phase 4 Ketamine;Placebo
15 A Randomized Controlled Comparison of Different Dose Combinations of Bupivacaine and Sufentanil on Epidural Analgesia Onset Time and Adverse Reactions During Labor Completed NCT03395600 Phase 4 B1S5;B125S5;B1S10
16 Levobupivacaine for Epidural Analgesia in Labour Completed NCT00929682 Phase 4 Randomization between two referenced treatments
17 Efficacy Of Scalp Block And Ultrasound Guided TAP Block With Clonidine As Adjuvant To Ropivacaine Versus Intravenous Fentanyl On Intraoperative Hemodynamics And Perioperative Analgesia In Abdominal Bone Flap Cranioplasties: A Prospective, Randomised, Double Blind Study Completed NCT03667352 Phase 4 Intravenous Fentanyl
18 Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial Completed NCT01966172 Phase 4 Ibuprofen;Gabapentin;Morphine;Paracetamol
19 Comparison of Intrathecal Morphine, Epidural Bupivacaine With Sufentanil and Systemic Patient Controlled Analgesia With Morphine for Analgesia After Colorectal Surgery: Prospective Randomised Study. Completed NCT03007121 Phase 4 Morphine intrathecal;Bupivacaine + Sufentanil epidural;Morphine intravenous
20 Evaluation of the Effect of Adding Magnesium Sulfate Infusion to Ketamine Infusion on Improvement of the Analgesic Efficacy in Cancer Breast Surgeries. Completed NCT04111848 Phase 4 Ketamine;ketamine and magnesium
21 Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections Completed NCT03105193 Phase 4 IV Saline bolus and infusion;IP Saline bolus and infusion;IV lignocaine bolus and infusion;IP Lignocaine bolus and infusion
22 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
23 Extension of the Analgesia of an Interscalene Block of the Brachial Plexus by Combined Injection of Dexamethasone and Dexmedetomidine, After Arthroscopic Shoulder Surgery: Randomized, Controlled, Double-blind Trial Recruiting NCT04394481 Phase 4 Dexmedetomidine;Ropivacaine;Dexamethasone
24 Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery (VATS) - A Randomized Controlled Trial. Recruiting NCT03809442 Phase 4 Ropivacaine + Ketamine;Ropivacaine + Tramadol;Ropivacaine + Midazolam;Ropivacaine + Dexmedetomidine;Ropivacaine + Dexamethasone;Ropivacaine
25 Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation: A Dose-exploration and Effectiveness Study Recruiting NCT04436224 Phase 4 Hydromorphone;Fentanyl;Butorphanol
26 Impact of Dexmedetomidine Supplemented Analgesia on Long-term Survival in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial Recruiting NCT03012971 Phase 4 Dexmedetomidine supplemented morphine analgesia;Morphine analgesia
27 Effects of Individualized Opioid Analgesia Versus Conventional Opioid Analgesia After Adenotonsillectomy in Children Not yet recruiting NCT04527393 Phase 4 Individualized oral morphine;Conventional oral morphine
28 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
29 Assessing the Impact of EXPAREL(R) on Opioid Use and Patient Reported Outcomes When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) Under Ultrasound Guidance for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries Terminated NCT01919190 Phase 4 EXPAREL;Placebo
30 Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia. Terminated NCT01882530 Phase 4 Paracetamol;Nefopam;Ketoprofen;Morphine
31 A Randomized, Open-label, Multicenter, Parallel-group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days Terminated NCT00421720 Phase 4 Sufentanil;Remifentanil
32 Use of Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy: Evaluation of Postoperative Pain and Opioid Consumption Terminated NCT04495374 Phase 4 Pregabalin 300mg
33 The Effect of Pectoralis Block on Analgesia After Simple Mastectomy Withdrawn NCT03143530 Phase 4 Normal saline injection;Ropivacaine Injection
34 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
35 Post-Operatory Analgesia in Newborn Infants: a Comparative Study of Fentanyl Versus Tramadol Completed NCT00713726 Phase 3 FentanyL;Tramadol
36 A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia-Multicentered, Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT02811991 Phase 2, Phase 3 Paracetamol injection;Normal Saline injection;Morhpine PCA
37 Is Continuous Wound Infusion With Ropivacaine Better Than Intrathecal Morphine for Post-caesarean Analgesia? A Prospective, Randomized, Controlled, Double Blinded Study Completed NCT02264821 Phase 3 ropivacaine infiltration;intrathecal morphine;placebo
38 Comparison of Perioperative Analgesia Between Intravenous Paracetamol and Fentanyl for Rigid Hysteroscopy Completed NCT04762147 Phase 3 paracetamol, the group P;fentanyl, group-F administered as an active comparator
39 Analgesia for Neonatal Circumcision: A Randomized Controlled Clinical Trial of EMLA Versus Combination of EMLA, Sucrose and Dorsal Penile Nerve Block or Ring Block Completed NCT02990364 Phase 3 Sucrose;Lidocaine;EMLA Topical Product
40 COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY. Completed NCT02185924 Phase 2, Phase 3 Parecoxib;CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%;N/S 0.9%
41 Continuous Regional Analgesia After Total Knee Arthroplasty. Normal Saline or Dextrose 5% in Water as Fluid Medium for Pre-Placement Expansion in Order to Facilitate the Catheter Passing Completed NCT00337597 Phase 3
42 A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Simple Bunionectomy Completed NCT03295721 Phase 3 HTX-011;Saline Placebo;Bupivacaine HCl
43 A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy Completed NCT03237481 Phase 3 HTX-011;Bupivacaine HCl;Saline placebo
44 Epidural Analgesia During Labour Randomized Clinical Trial Comparing Patient Controlled Epidural Analgesia Versus Patient Intermittent Epidural Boluses With Levobupivacaine Completed NCT03133091 Phase 3 PIEB: Patient Intermittent Epidural Boluses;PCEA: Patient Controlled Epidural Analgesia
45 Laparoscopic Guided Transversus Abdominis Plane Block for Postoperative Analgesia After Pediatric Laparoscopic Surgery. Recruiting NCT03388671 Phase 2, Phase 3 Bupivacaine
46 Comparative Study Between Intraperitoneal Administration of Either Bupivacaine and Tramadol Versus Bupivacaine and Dexmedetomedine for Analgesia After Abdominal Laparoscopic Cancer Surgeries. A Prospective Randomized Pilot Study Recruiting NCT04813016 Phase 2, Phase 3 Tramal 1;Tramal 2;Dexmedetomidine 1;dexmedetomidine 2
47 Neuroimaging Studies of Dexmedetomidine- and Ketamine-Induced Analgesia Not yet recruiting NCT04656470 Phase 2, Phase 3 Dexmedetomidine;Ketamine
48 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia Not yet recruiting NCT04738357 Phase 3 HSK21542;Placebo
49 A Non-Inferiority Randomized Trial Comparing the Impact of Thoracic Epidural Analgesia Versus Surgical Site Infiltration With Liposomal Bupivicaine on the Postoperative Recovery of Patients Following Open Gynecologic Surgery Not yet recruiting NCT04117074 Phase 3 Liposomal bupivacaine
50 Evaluation of the Analgesia by Serratus Plane Block During Pleural Drainage in Intensive Care Unit. Not yet recruiting NCT03984656 Phase 3 lidocaine treatment;serratus plane block treatment

Search NIH Clinical Center for Agnosia

Cochrane evidence based reviews: agnosia

Genetic Tests for Agnosia

Anatomical Context for Agnosia

MalaCards organs/tissues related to Agnosia:

40
Brain, Cortex, Temporal Lobe, Eye, Parietal Lobe, Occipital Lobe, Thyroid

Publications for Agnosia

Articles related to Agnosia:

(show top 50) (show all 2032)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
2
Subcortical deafness as a subtype of auditory agnosia after injury of bilateral auditory radiations caused by two cerebrovascular accidents - normal auditory brainstem responses with I-VII waves and abolished consciousness of hearing. 61
33573440 2021
3
Developmental Dyspraxia in Children With Learning Disorders: Four-Year Experience in a Referred Sample. 61
33103525 2021
4
Alzheimer Disease: Controversies in Basic Science Research, Different Theories, and Reasons for Failed Trials. 61
33807508 2021
5
Case study: A selective tactile naming deficit for letters and numbers due to interhemispheric disconnection. 61
33770548 2021
6
Complementary deficits in perceptual classification in pure alexia and acquired prosopagnosia - New insights from two classic cases. 61
33676958 2021
7
Temporo-parietal brain regions are involved in higher order object perception. 61
33757908 2021
8
Validity of the Occupational Performance Scale of the Sensory Processing Three Dimensions Measure. 61
33657351 2021
9
Awareness and knowledge of developmental coordination disorder: A survey of caregivers, teachers, allied health professionals and medical professionals in Australia. 61
33140459 2021
10
New insights into the anatomo-functional architecture of the right sagittal stratum and its surrounding pathways: an axonal electrostimulation mapping study. 61
33389045 2021
11
Auditory agnosia with anosognosia. 61
33647851 2021
12
Simultaneous auditory agnosia: Systematic description of a new type of auditory segregation deficit following a right hemisphere lesion. 61
33360763 2021
13
Considerations on "mirror agnosia". 61
33647850 2021
14
Profile of language abilities in a sample of adults with developmental disorders. 61
33200857 2021
15
Neuropharmacological potentials of β-carboline alkaloids for neuropsychiatric disorders. 61
33359647 2021
16
Examining academic confidence and study support needs for university students with dyslexia and/or developmental coordination disorder. 61
33098245 2021
17
The experiences of foundation doctors with dyspraxia: a phenomenological study. 61
33559779 2021
18
Overview of COVID-19 and neurological complications. 61
33583157 2021
19
Selective defects of face familiarity associated to a left temporo-occipital lesion. 61
32648048 2021
20
Vestibular agnosia in traumatic brain injury and its link to imbalance. 61
33367536 2021
21
Cerebral trauma-induced dyschromatopsia in the left hemifield: case presentation. 61
33504343 2021
22
Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson's disease and Dementia with Lewy Bodies: A systematic review. 61
32869379 2021
23
The roles of language use and vocabulary size in the emergence of word-combining in children with complex neurodevelopmental disabilities. 61
32460930 2021
24
Children and young people's experiences of living with developmental coordination disorder/dyspraxia: A systematic review and meta-ethnography of qualitative research. 61
33661934 2021
25
Medical teachers' opinions about students with neurodevelopmental disorders and their management. 61
33407399 2021
26
Three types of agnosia. 61
33509822 2021
27
[Executive functions disorders in children with dyslexia]. 61
33728849 2021
28
The unmet clinical needs of children with developmental coordination disorder. 61
33504966 2021
29
Driving Skills of Individuals With and Without Developmental Coordination Disorder (DCD/Dyspraxia). 61
33762916 2021
30
Mobile EEG reveals functionally dissociable dynamic processes supporting real-world ambulatory obstacle avoidance: Evidence for early proactive control. 61
33465827 2021
31
Nonconvulsive Status Epilepticus With Neuropsychological Symptoms: Two Case Reports. 61
33264155 2020
32
Asymmetric Bálint's syndrome with multimodal agnosia, bilateral agraphesthesia, and ineffective kinesthetic reading due to subcortical hemorrhage in the left parieto-occipito-temporal area. 61
33103577 2020
33
A case of inferior frontal gyrus infarction manifesting Gerstmann syndrome. 61
33175666 2020
34
Primitive Reflex Activity in Relation to the Sensory Profile in Healthy Preschool Children. 61
33172138 2020
35
A Rare Clinical Antity; Pure Gerstmann Syndrome. 61
32912538 2020
36
Left Parietal Tumors Presenting with Smartphone Icon Visual Agnosia: Two Cases of a Modern Presentation of Gerstmann Syndrome. 61
32673807 2020
37
The size-weight illusion in visual form agnosic patient DF. 61
32804579 2020
38
A case of mirror image agnosia and mirrored self-misidentification syndrome in schizophrenia without dementia or structural abnormalities. 61
32726169 2020
39
Clinical Features, Risk Factors, and Endoscopic Treatment of Bezoars: A Retrospective Analysis from a Single Center in Northern China. 61
33027245 2020
40
Coordination difficulties and self-esteem: The views of children, adolescents, and their parents. 61
32329906 2020
41
Immersive Virtual Environments and Wearable Haptic Devices in rehabilitation of children with neuromotor impairments: a single-blind randomized controlled crossover pilot study. 61
33115487 2020
42
Neuropsychological and behavioral disorders as presentation symptoms in two brothers with early-infantile Niemann-Pick type C. 61
32921771 2020
43
Diagnosis of oculomotor anomalies in children with learning disorders. 61
31869866 2020
44
Sexual Behavioral Disinhibition Associated with Nucleus Lentiformis Lesion: A Forensic Neuroscience Perspective Through a Case. 61
32525581 2020
45
The influence of type of feedback during tablet-based delivery of intensive treatment for childhood apraxia of speech. 61
32693310 2020
46
Hammering that Nail: Varied Praxis Motor Skills in Younger Autistic Children. 61
31297643 2020
47
Pilot Study to Measure Deficits in Proprioception in Children With Somatodyspraxia. 61
32804633 2020
48
Gerstmann Syndrome. 61
32852667 2020
49
Altered large-scale organization of shape processing in visual agnosia. 61
32574843 2020
50
Music processing deficits in Landau-Kleffner syndrome: Four case studies in adulthood. 61
32442777 2020

Variations for Agnosia

ClinVar genetic disease variations for Agnosia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SIL1 NC_000005.10:g.139189727_139201554del Deletion Pathogenic 812923 GRCh37: 5:138525416-138537243
GRCh38:

Expression for Agnosia

Search GEO for disease gene expression data for Agnosia.

Pathways for Agnosia

GO Terms for Agnosia

Cellular components related to Agnosia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.09 TAC1 POMC PNOC PDYN OXT NPFF
2 integral component of plasma membrane GO:0005887 10 TYROBP TRPV1 TRPA1 SCN9A OPRM1 OPRL1
3 axon GO:0030424 9.8 TAC1 SCN9A OPRM1 CCK CALCA
4 dendrite GO:0030425 9.7 TRPV1 PNOC PDYN OPRM1 OPRK1 NPFF
5 perikaryon GO:0043204 9.62 OPRM1 OPRK1 NPFF CCK
6 axon terminus GO:0043679 9.56 PNOC PDYN OPRK1 NPFF
7 terminal bouton GO:0043195 9.54 OXT CCK CALCA
8 neuron projection GO:0043005 9.5 TRPV1 SCN9A OPRM1 OPRL1 OPRK1 FOS
9 neuronal cell body GO:0043025 9.17 TRPV1 TAC1 PNOC PDYN OPRK1 CCK

Biological processes related to Agnosia according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.28 TYROBP POMC PNOC OXT OPRM1 OPRL1
2 G protein-coupled receptor signaling pathway GO:0007186 10.11 TAC1 POMC PNOC PDYN OXT OPRM1
3 inflammatory response GO:0006954 10.01 TRPV1 TAC1 SCN9A FOS CALCA
4 chemical synaptic transmission GO:0007268 9.95 TAC1 PNOC PDYN OPRK1 NPFF
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.91 TRPV1 TAC1 OXT OPRM1 NPFF CALCA
6 female pregnancy GO:0007565 9.83 PNOC OXT FOS
7 regulation of blood pressure GO:0008217 9.81 TAC1 POMC CALCA
8 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.81 OPRM1 OPRL1 OPRK1
9 excitatory postsynaptic potential GO:0060079 9.8 TRPV1 OPRM1 NPFF
10 response to cocaine GO:0042220 9.77 OXT OPRM1 OPRK1
11 cellular response to nerve growth factor stimulus GO:1990090 9.77 TRPV1 TAC1 CALCA
12 response to morphine GO:0043278 9.76 TAC1 OPRM1 OPRK1 NPFF
13 negative regulation of blood pressure GO:0045776 9.73 OXT OPRL1 CALCA
14 eating behavior GO:0042755 9.72 OXT OPRM1 OPRL1 OPRK1 CCK
15 response to pain GO:0048265 9.71 TRPV1 TRPA1 TAC1 CALCA
16 estrous cycle GO:0044849 9.69 OPRM1 OPRL1 OPRK1
17 negative regulation of cAMP-mediated signaling GO:0043951 9.68 OPRM1 OPRL1
18 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.67 TRPV1 CALCA
19 positive regulation of ossification GO:0045778 9.67 TAC1 OXT
20 behavior GO:0007610 9.67 OPRL1 OPRK1
21 negative regulation of heart rate GO:0010459 9.67 TRPV1 TAC1 NPFF
22 positive regulation of renal sodium excretion GO:0035815 9.66 TAC1 OXT
23 behavioral response to pain GO:0048266 9.65 TRPV1 SCN9A
24 maternal behavior GO:0042711 9.65 OXT OPRK1
25 sleep GO:0030431 9.65 OXT FOS
26 opioid receptor signaling pathway GO:0038003 9.65 OPRM1 OPRL1 OPRK1
27 sensory perception GO:0007600 9.65 PNOC PDYN OPRM1 OPRL1 OPRK1
28 negative regulation of appetite GO:0032099 9.64 NPFF CCK
29 regulation of sensory perception of pain GO:0051930 9.63 OXT OPRM1 OPRL1 OPRK1 NPFF CCK
30 positive regulation of sensory perception of pain GO:1904058 9.62 OPRL1 CCK
31 acute inflammatory response to antigenic stimulus GO:0002438 9.62 OPRM1 NPFF
32 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.61 OPRM1 OPRL1
33 conditioned place preference GO:1990708 9.58 OPRL1 OPRK1
34 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.58 TRPV1 TRPA1
35 thermoception GO:0050955 9.57 TRPV1 TRPA1
36 positive regulation of gastric acid secretion GO:0060454 9.54 TRPV1 OPRL1
37 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.52 OPRM1 OPRK1
38 sensory perception of pain GO:0019233 9.5 TRPV1 TRPA1 TAC1 SCN9A OPRM1 OPRL1
39 neuropeptide signaling pathway GO:0007218 9.28 TAC1 POMC PNOC PDYN OPRM1 OPRL1

Molecular functions related to Agnosia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.58 OPRM1 OPRL1 OPRK1
2 hormone activity GO:0005179 9.56 POMC OXT CCK CALCA
3 calcium-release channel activity GO:0015278 9.43 TRPV1 TRPA1
4 opioid receptor binding GO:0031628 9.37 PNOC PDYN
5 neuropeptide binding GO:0042923 9.33 OPRM1 OPRL1 OPRK1
6 opioid peptide activity GO:0001515 9.32 PNOC PDYN
7 opioid receptor activity GO:0004985 9.13 OPRM1 OPRL1 OPRK1
8 neuropeptide hormone activity GO:0005184 8.92 PNOC OXT NPFF CCK

Sources for Agnosia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....